Takeda's pipeline has taken a hit as the company reported a safety signal from a midstage narcolepsy program. The Japanese pharma doubled down on gene therapy with a licensing deal with Selecta Biosciences to work on lysosomal storage disorders. Takeda and Moderna have pinpointed how contaminants landed in three lots of COVID-19 vaccines in Japan. And more.